CHINARES PHARMA's stock surged 5.25% during intraday trading on Friday, extending its recent rally. The pharmaceutical company has seen significant upward momentum following the release of its latest financial results.

The sharp rise comes after CHINARES PHARMA reported annual results that exceeded market expectations. The company achieved group revenue of RMB 269.574 billion, representing a year-on-year increase of 4.62%, while profit attributable to shareholders reached RMB 4.045 billion, up 20.73% from the previous year. Earnings per share stood at RMB 0.64, and the company declared a final dividend of RMB 0.122 per share, which represents an increase of approximately 1.35 times compared to the previous year.

Analysts at CLSA noted that both revenue and profit for the full year surpassed market expectations. Additionally, China Merchants Securities International highlighted that while management didn't provide specific numerical guidance for the 2026 fiscal year, they conveyed several positive qualitative signals during the results briefing. The company aims to achieve high single-digit revenue growth and maintain a good growth rate in net profit for the 2026 fiscal year. The dividend payout ratio will be maintained at 30%, with potential increases if no major acquisitions occur. The company also expects impairment pressure to decrease significantly in 2025 and plans to continue its strategic mergers and acquisitions in the blood products sector.